no more injections or cotton pads, or packing needles for trips, or sight-injection pain, etc. etc. I have not tried it as I have been off any medication for about a year. But nice to know that If I have to get back to artificially supressing my immune system, the pill is there. Thanks Novartis. Below is some info i found out about. The side effects are there of course. I rather be dizzy and have full use of my limbs though.
If anyone out there is using Gilenya please let me know how it is going. –Dan
On September 22, 2010, fingolimod became the first oral disease modifying drug approved by the Food and Drug Administration as Gilenya to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis.
Fingolimod (rINN, codenamed FTY720) is an immunosuppressive drug. It is derived from the myriocin (ISP-1) metabolite of the fungus Isaria sinclairii. It is a structural analogue of sphingosine and gets phosphorylated by sphingosine kinases in the cell (most importantly sphingosine kinase 2). The molecular biology of phospho-fingolimod is thought to lie in its activity at one of the five sphingosine-1-phosphate receptors, S1PR1. It can sequester lymphocytes in lymph nodes, preventing them from moving to the central nervous system for auto-immune responses in multiple sclerosis and was originally proposed as a anti-rejection medication indicated post-transplantation. It has been reported to stimulate the repair process of glial cells and precursor cells after injury. Fingolimod has also been reported to be a cannabinoid receptor antagonist, a cPLA2 inhibitor  and a ceramide synthase inhibitor.